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Objective: To compare the efficacy and safety of a 3-day regimen of clindamycin vaginal ovules with a 7-day
regimen of clindamycin vaginal cream for the treatment of bacterial vaginosis (BV).
Methods: WomenwithaclinicaldiagnosisofBVweretreatedwitha3-daycourseofclindamycin ovulesora7-day
course of clindamycin cream administered intravaginally. Three hundred and eighty-four patients received study
drug and were included in the evaluable patient population (ovule group, n = 204; cream group, n = 180).
Assessments included pelvic examination and diagnostic testing. Primary efficacy endpoints were a resolution of
two of three diagnostic criteria at the first follow-up visit and three of three diagnostic criteria at the second.
Results: Curerates in the evaluable patient population were similar between treatmentgroups:53.7% (109/204)
for the ovule group and 47.8% (85/180) for the cream group (p = 0.2471, 95% CI 4.1–16.0%). The most
commonly reported medical event, vulvovaginal pruritus, had similar incidence in both treatment groups.
Conclusions: A 3-day course of clindamycin vaginal ovules is as effective and well-tolerated as a 7-day course of
clindamycin vaginal cream in the treatment of BV.
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Bacterial vaginosis (BV) is a commonly reported
vaginal infection among women of child-bearing
age. Among pregnant women, BV has an inci-
dence of 15% to 20%l and has been associated with
an increased risk of pregnancy complications,
includingpreterm labor,low birth weight,chorio-
amnionitis, pelvic inflammatory disease, and
postpartum endometritis2–5. In nonpregnant
women, untreated asymptomatic BV is associated
with complications following gynecologic proce-
dures, in addition to presenting as a symptomatic
infection1,2,6,7.
Systemic or local antibiotic therapy remains the
standard regimen for the treatment of BV. The
most widely recommended therapy is oral metro-
nidazole (2 g single dose or 500 mg twice daily for
7 days)6,8. Its use, however, is constrained by the
potential for systemic adverse effects; thus, many
Infect Dis Obstet Gynecol 2001;9:9–15
Grant sponsor: Pharmacia and Upjohn, Bridgewater, NJ.
Correspondenceto: Jack Sobel,MD, Division of InfectiousDiseases, Detroit Medical Center, Wayne State University Schoolof
Medicine, 3990 John R. Street, Detroit, MI 48201, USA
Clinical study 9clinicians may prefer local antibiotic therapy for
the routine treatment of BV9. Currently used
intravaginal therapies are clindamycin vaginal
cream (2%, once daily for 3 or 7 days) and metro-
nidazolegel(0.75%,onceortwicedailyfor5days).
Several studies that have compared the oral and
local therapeutic regimens have found similar
efficacy and safety profiles when clindamycin is
used in the treatment of BV6,10–13. In 1993, it was
demonstrated that a 3-day course of clindamycin
vaginal cream wasas effective as thestandard7-day
regimen14. Subsequent studies have confirmed the
efficacy of this regimen in thetreatment ofBV15,16.
Sincethen,the3-daycoursehas beenapprovedfor
the treatment of uncomplicated BV in several
European countries and recently (March, 1998) in
the United States. Interest in both a shorter
therapeutic regimen and an alternative vaginal-
dosage form led to trials with the clindamycin
vaginal ovule. In this study, efficacy and safety of
a 3-day clindamycin vaginal ovule regimen
are compared to those of the standard 7-day
clindamycin vaginal cream regimen for the treat-
ment of BV.
SUBJECTS AND METHODS
Prior to initiation, the study was reviewed and
approved by independent review committees
responsible for ensuring the rights and safety of
the research subjects, in accordance with the
Declaration of Helsinki and the National and
International Good Clinical Practice Guidelines
and Ethical Standards, including those of
the countries in which the study was conducted.
It was conducted in accordance with the
ethical principles that have their rights and
origins in the Declaration of Helsinki. Signed,
written, informed consent was required for all
patients.
Patients to be included in this multicenter,
prospective, randomized, observer-blinded study
were symptomatic women aged 16–60 years
having a clinical diagnosis of BV with fulfillment
of all the following Amsel criteria: (1) vaginal
fluid pH > 4.5, (2) ‘fishy’ amine odor upon
addition of potassium hydroxide (KOH) to the
vaginal fluid, and (3) presence of clue cells in the
vaginal fluid upon microscopic examination.
These criteria were selected based on their
widely accepted reliability as diagnostic indicators
of BV17. In addition, all subjects were required
to have a Gram stain score compatible with BV
based on the 0–10 scoring system and colleagues
of Nugent and colleagues18. Criteria for exclusion
from the study were as follows: allergy to
clindamycin or lincomycin, pregnancy or
breast-feeding; systemic or vaginal antimicrobial
therapy within the previous 2 weeks; previous
enrollment in the study, necessity of using
nonprotocol antibiotics; positive cultures or tests
for Neisseria gonorrhoeae, Candida albicans,
Trichomonas vaginalis or Chlamydia trachomatis;
atrophic vaginitis; clinical evidence of herpes
virus infection; and anticipation of menses
during treatment or follow-up visits. Patients
were also excluded when they had any other
condition or disease that, in the investigator’s
opinion, should exclude the patient from the
study.
Treatment regimens were either clindamycin
vaginal ovule, 100 mg, digitally inserted intra-
vaginally at bedtime for 3 consecutive days, or
clindamycin vaginal cream 2%, 5 g (1 applicator
equivalent to 100 mg clindamycin), applied intra-
vaginally at bedtime for 7 consecutive days. The
100-mg dose of clindamycin ovule was selected
based on its milligram equivalence to one
applicator of clindamycin cream. Patients were
randomly assigned to receive one of the drug
regimensbasedonarandomlist ofpatientnumbers
at a 1:1 ratio.
Following informed consent, pretreatment
evaluations included history and pelvic examin-
ation; description of vaginal discharge; pH of
vaginal fluid; smear of vaginal fluid for clue cells;
test for fishy odor after addition of KOH; Gram
stain score of vaginal fluid; and appropriate
diagnostic testing for T. vaginalis, C. albicans,
C. trachomatis and N. gonorrhoeae. Follow-up
examinations (12–16 days and 18–52 days after
treatment) included repeat diagnostic tests for pH,
clue cells and odor; repeat Gram stain; description
of vaginal discharge; vulvovaginal examination;
tests for C. albicans and T. vaginalis if symptomatic;
treatment compliance information (first follow-up
only); and assessment of medical events and
concomitant medications.
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determined by three criteria (amine odor, pH and
clue cells). Cure was defined as a resolution of two
of three diagnostic criteria at the first follow-up
visit and three of three criteria at the second visit.
Secondary efficacy measures included patient
evaluation ofefficacyandGram stain score.Patient
evaluations of efficacy, using the terms ‘cured’,
‘improved’ or ‘failed’ were completed at the
second follow-up visit. Gram stain outcomes for
vaginal fluid smears, obtained at both first and
second follow-up visits, were evaluated for BV
usingastandardizedmorphotypescoringsystem18.
Patients in the study were considered non-
evaluable if any of the following applied: failure to
meet selection criteria, less than 3daysoftreatment
with ovules (or lapses in ovule dosing), less than
6daysormorethan8daysoftreatment with cream
(with an allowable lapse of 1 day), menses during
protocol therapy or follow-up visit, nonprotocol
systemic or vaginal antimicrobial therapy during
protocol therapy or before a follow-up visit (with
the exception of patients deemed to be treatment
or side-effect failures), failure to return for
follow-up visit (except for clinical or side-effect
failures), douching during protocol therapy or
within 2 days of a follow-up visit, development of
a symptomatic or concomitant genital infection
(i.e. yeast vaginitis or trichomoniasis), or for any
other reason that in the opinion of the investigator
and monitor made the patient nonevaluable.
All patients enrolled in the study were included
in thesafety analysis unless no protocolmedication
was taken. Safety was evaluated by patient-
reported medical events. The reporting period for
medical events began after the first dose of study
medication and ended at the final follow-up visit.
Additional events reported were those occurring
outside the medical events-reporting period
judgedby theinvestigator as possiblyrelated to the
study medication. When study patients became
pregnant while receiving study medication or
within 30 days of discontinuation, appropriate
measures were taken to follow the pregnancyuntil
its completion, and results were reported for
exposure in utero.
Data quality-control measures were imple-
mented to ensure the reliability of the data
collected, includingperiodic visits to study sites by
the sponsor to ensure proper adherence to study
protocol and routine site audits to ensure accuracy
and consistency of data collected.
All statistical tests were two-sided tests; p values
£ 0.05 weredeemed statistically significant.Differ-
ences between treatment groups for efficacy
endpoints were analyzed using either Pearson c2
tests or Cochran–Mantel–Haenszel tests. Other
categorical variables (race, medical history,
pretreatment pelvic examination abnormalities
and proportion of patients reporting medical
events) were analyzed using Fisher’s exact test.
Continuous variables (age, weight and previous
episodes of BV) were analyzed using one-way
analysis of variance. Categorical variables (other
than medical events) were analyzed using Pearson
c2 tests (with the exclusion of the nonassessable
variable for the primary efficacy measure). The
proportion of patients reporting at least one
medical event and the proportion of patients
reporting at least one drug-related medical event
were analyzed using Fisher’s exact test. Based on
theprobabilityofcorrectlyconcludingthattherate
of success for the clindamycin vaginal ovule was
not more than 15% less than the expected 65%
success rate for the cream, the power was 0.81.
RESULTS
Of the intent to treat (ITT) patients, 384 patients
were considered evaluable, 204in the ovule group
and 180 in the cream group. The main reasons for
nonevaluability are summarized in Figure 1. The
most common reasons for nonevaluability were
failure to meet inclusion criteria postenrollment
and noncompliancewith the dosing regimen. The
percentageofpatientsconsiderednonevaluablefor
eachprimaryreason wassimilar betweentreatment
groups.
Table 1 summarizes demographic data for
patients in the ITT population. There were no
statistically significant differences in patient demo-
graphics (age, weight and race) for ITT patients
between treatment groups. The demographic
profile for the evaluable patient population was
similar to that of the ITT population (data not
shown).
No statistically significant differences were
noted between treatment groupsin either the ITT
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present or past medical history. The number of
previousepisodesofBV, aswell as theincidenceof
abnormal findings in the pelvic examination, was
also similar between treatment groups.
Fourteen-day assessment
Based on three diagnostic criteria (clue cells, pH
and amine odor), 86.2% of patients in the ovule
group (175/204) were cured compared to 75.4%
of patients in the cream group (135/180), reflect-
ing statistical significance (p = 0.0052; Table 2).
Based on two diagnostic criteria (clue cells and
amine odor only), 81.3% of patients (165/204) in
the ovule group were cured compared to 72.6%
(130/180) of patients in the cream group
(p = 0.0173). There was no significant difference
between treatment groups regarding the distri-
bution among Gram stain scores. The majority of
patients had normal or intermediate scores at the
first follow-up visit.
Thirty-five-day assessment
By the second follow-upvisit, there was no signif-
icant difference between treatment groups for the
evaluable patient population, although cure rates
were lower (59.7–61.2%) using three diagnostic
criteria. Similarly, the cure rate was 78.9% in each
group using two diagnostic criteria. The higher
cure rate with two vs. three diagnostic criteria
reflects the reduced stringency of the efficacy
criteria and the influence of the pH criterion in
lowering the defined cure rate.
No significant differences were noted between
treatment groupsregardingthedistributionamong
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Variable
CVO
(n = 327)
CVO
(n = 335)
Total
(n = 662)
Treatment
p value*
Age (years)
Mean ± SD
Range
Weight (kg) (mean ± SD)
Range; number reporting
Race (n(%))
White
Black
Oriental/Asian
Hispanic
Other
29.5 ± 8.3
16–55
69.0 ± 19.4
40–172; n = 314
113 (34.6)
148 (45.3)
003 (0.9)
061 (18.7)
002(0.6)
29.5 ± 8.0
17–58
69.3 ± 17.5
42–133; n = 329
112 (33.4)
149 (44.5)
002 (0.6)
068 (20.3)
004(1.2)
29.5 ± 8.2
16–58
69.2 ± 18.4
40–172; n = 643
225 (34.0)
297 (44.9)
005 (0.8)
129 (19.5)
006(0.9)
0.8961
0.8286
0.8340
CVO, clindamycin vaginal ovule, 3-day treatment; CVC, clindamycin vaginal cream, 7-day treatment; *for age and weight, based on one-way
analysis of variance (excluding ‘not reported’); for race, based on two-tailed Fisher’s exact test (based on white, black and all other races)
Table 1 Patient demographics (intent to treat (ITT) patients)
Figure 1 Algorithm of patient selection. BV, bacterial
vaginosisGram stain score categories. The majority of
patients had normal Gram stain scores (ovule
group, 57.8%; cream group, 58.9%).
ITT population
Overall clinical outcome was also similar between
treatment groups when assessed in the ITT
patient population (Table 3). In the ITT patient
population, a significantly greater percentage of
patients within the ovule group was cured at the
first follow-up visit relative to the cream group
using three diagnostic criteria (88.8% vs. 80.8%;
p = 0.0061) and also when using two diagnostic
criteria (84.3% vs. 77.3%; (p = 0.0134). Cure rates
at the second visit ranged from 78.9% to 80.9%. A
similar percentage of patients within each treat-
ment group (79.1% of the reporting patientsin the
ovule group, 151/191; 83.7% of the reporting
patients in the cream group, 128/153) rated their
vaginal infections as having been cured.
Safety
Safety was evaluated by patient-reported medical
events. No statistically significant difference
(p = 0.740) between the treatment groups was
found in the percentage of patients reporting at
least one medical event (33.3% ovule group,
109/327; 31.9% cream group, 107/335). The
percentage of patients reporting medical events
was similar between treatment groups, with the
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14-Day assessment 35-Day assessment
Number (%) of patients Number (%) of patients
Outcome
CVO
(n = 204)
CVC
(n = 180) p value*
CVO
(n = 204)
CVC
(n = 180) p value*
Three diagnostic criteria
Cure
Failure
Two diagnostic criteria
Cure
Failure
Gram stain score
Normal (0–3)
Intermediate (4–6)
Compatible with BV (7–10)
175 (86.2)
028 (13.8)
165 (81.3)
38 (18.7)
110 (55.8)
63 (32.0)
24 (12.2)
135 (75.4)
39 (21.8)
130 (72.6)
44 (24.6)
74 (43.8)
72 (42.6)
23 (13.6)
0.0052
0.0173
0.0672
114 (59.7)
77 (40.3)
150 (78.9)
40 (21.1)
108 (57.8)
41 (21.9)
38 (20.3)
93 (61.2)
59 (38.8)
120 (78.9)
32 (21.1)
89 (58.9)
33 (21.9)
29 (19.2)
0.7781
1.0000
0.9642
CVO, 3-day clindamycin vaginal ovule; CVC, 7-day clindamycin vaginal cream; *based onc
2; BV, bacterial vaginosis
Table 2 Clinicalcure rates and Gram stain results at 14- and 35-day assessments among evaluable patient population
Three diagnostic criteria Two diagnostic criteria
Number (%) of patients Number (%) of patients
Outcome
CVO
(n = 327)
CVC
(n = 335)
p value*
95% CI**
CVO
(n = 327)
CVC
(n = 335)
p value*
95% CI**
Cure
Failure
Nonassessable
134 (56.3)
104 (43.7)
89
113 (50.4)
111 (49.6)
111
0.2072
–3.2, 14.9
164 (68.3)
76 (31.7)
87
142 (62.3)
86 (37.7)
107
0.1689
–2.6, 14.7
CVO, 3-day clindamycin vaginal ovule; CVC, 7-day clindamycin vaginal cream; *based onc
2 test (three criteria, Breslow–Day test p value =
0.1724) or Cochran–Mantel–Haenszel test (two criteria, Breslow–Day test p value = 0.0665); **two-sided 95% CI for difference in cure
rates between CVO and CVC groups
Table 3 Clinical outcome for ovule (CVO) and cream (CVC) groups using three and two diagnostic criteria for the
intent to treat (ITT) populationexception of vaginal pain (ovule group, 3.4%;
cream group, 0.9%), flu syndrome (ovule group,
0.9%; cream group, 2.7%), and headache
(ovule group, 6.4%; cream group, 3.6%). Vaginal
candidiasis was reported in five (1.5%) patients in
the ovule group and three (0.9%) in the cream
group. The vast majority of medical events
reported in both treatment groupswere of mild to
moderate intensity (ovule group,95.2%, 177/186;
cream group,87.1%, 149/171). Nine events in the
ovule group (4.8%) and 19 events in the cream
group(11.1%)wereratedassevere (interfered with
usual function). Fungal infections affecting either
the skin or the urogenital system occurred in a
similar percentage of patients in both treatment
groups. The most frequently reported medical
event was vulvovaginal itching (7.3% in the ovule
group, 8.4% in the cream group). Very few
patients discontinued medication because of
medical events (ITT patients, 1 of327 in the ovule
group, 6 of 335 in the cream group).
DISCUSSION
Therapeutic options for practitioners in the
treatment of BV have increased from oral metro-
nidazole to better tolerated and more preferred
topical treatments, metronidazole gel and clinda-
mycin cream. Comparative studies of these
standard therapies have revealed no differences in
efficacy or safety when used in the treatment of
BV6,10–13. Topical regimens also offer the signifi-
cantadvantage offewer unwantedsystemic effects.
Nonetheless, these treatments are not without
inconveniences, and patient compliance and pref-
erenceareanimportantconsiderationforthetreat-
ment of BV in the general population.The search,
therefore, continues for faster, more convenient
alternatives for the treatment of BV. The vaginal
ovule represents a more convenient, less messy
alternative, and women may prefer this form of
dosing to conventional cream applicators. More-
over, the shortened 3-day regimen and
once-per-daydosingwill likely facilitate improved
patient compliance and adherence to therapy.
This study demonstrates that a 3-day course of
clindamycin vaginal ovules (100-mg ovule,
administered intravaginally at bedtime for 3
consecutivedays)is as effective as a 7-day courseof
clindamycinvaginalcream(5 g(1 applicatorequals
100 mg clindamycin) administered intravaginally
at bedtime for7 consecutive days) in thetreatment
of symptomatic BV. Assessment of cure rates using
either two diagnostic criteria (clue cells and amine
odor) or three diagnostic criteria (clue cells,
amine odorand pH) consistently demonstrated no
significant difference between the two treatment
regimens. The influence of the pH criterion in
lowering the observed cure rate is noteworthyand
suggests that pH may be a less reliable diagnostic
marker of cure. Nonetheless, inclusion of the pH
criterionhadnoeffectontheobserved similarity in
efficacy of the two treatment regimens.
No significant difference in the safety of these
two alternative clindamycin dosing regimens was
observed in the current study. Incidence of
medical events was similar for both treatment
groups, and most events were of mild to moderate
intensity. Incidence of fungal infections and
vulvovaginal disorder (mainly vulval and vaginal
itching) was also similar between treatment
groups. Very few patients discontinued medi-
cation because of medical events. No significant
safety problemwith the clindamycin vaginal ovule
was observed. Short-term therapy with clinda-
mycin vaginal ovules as demonstrated in this study
is therefore effective and well-tolerated and offers
women a shortened, more convenient dosing
alternative for the treatment of BV.
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